McKesson (MCK) Tops Q1 EPS by 2c, Revenues Miss; Offers FY19 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to McKesson (MCK) Tops Q1 EPS by 2c, Revenues Miss; Offers FY19 EPS Outlook
July 27, 2018 7:15 AM EDT
Baird lowered its price target on McKesson (NYSE: MCK) to $134.00 (from $141.00) while maintaining a Neutral rating. MCK claims in-line performance across all three segments. However, YY EBIT facts: U.S. +2% on easy/transitory prior-year comparison, EU -12%, Med-Surg flat, Other -8%. Three of... More
July 25, 2018 12:04 PM EDT
By Lewis Krauskopf
NEW YORK (Reuters) - Uncertainty over potential actions to reduce prescription drug costs and competitive threats have taken a toll this year on shares of companies in the U.S. pharmaceutical supply chain. They get their chance to change investor sentiment with quarterly earnings reports in the coming days.
Prescription drug wholesalers, drug store chains and pharmacy benefit managers generally have seen their stock prices tumble this year, even as the overall S&P 500 healthcare sector has gained 6 percent.
Six S&P 500 stocks - CVS Health Corp (NYSE:... More
